Skip to main content

Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC

*September 2023*

SINGAPORE — Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in “clinically meaningful and durable efficacy” in patients with advanced¬†EGFR-mutated non-small cell lung cancer (NSCLC), according to the phase II HERTHENA-Lung01 trial.

Among the 225 patients included in the study, the confirmed objective response rate (ORR) was 29.8% (95% CI 23.9-36.2), with a median duration of response of 6.4 months, reported Helena A. Yu, MD, of Memorial Sloan Kettering Cancer Center in New York City, during the World Conference on Lung Cancer. Read more.